Human coagulation factor viii/von willebrand factor complex
Voncento (human coagulation factor viii/von willebrand factor complex) is an unknown pharmaceutical. Human coagulation factor viii/von willebrand factor complex was first approved as Voncento on 2013-08-12. It has been approved in Europe to treat hemophilia a and von willebrand diseases.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| von willebrand factor/coagulation factor viii complex (human) | Biologic Licensing Application | 2010-08-20 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
172 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemophilia a | D006467 | EFO_0007267 | D66 | 25 | 23 | 50 | 28 | 41 | 152 |
| Von willebrand diseases | D014842 | EFO_0003910 | D68.0 | — | 2 | 9 | 3 | — | 13 |
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | 1 | 1 | 2 | 1 | 3 | 7 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | 1 | 1 | 1 | 2 | 2 | 6 |
| Hemostatic disorders | D020141 | — | — | 1 | 2 | 1 | 2 | 1 | 6 |
| Hemophilia b | D002836 | — | D67 | — | — | — | 2 | 2 | 4 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | 1 | 3 | 4 |
| Inherited blood coagulation disorders | D025861 | — | — | — | — | 1 | 1 | — | 2 |
| Joint diseases | D007592 | — | M12.9 | — | — | — | 1 | — | 1 |
| Blood platelet disorders | D001791 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhagic disorders | D006474 | — | D69.9 | — | — | 1 | — | 1 | 2 |
| Inborn genetic diseases | D030342 | EFO_0000508 | — | — | — | 1 | — | — | 1 |
| Coagulation protein disorders | D020147 | — | — | — | — | 1 | — | — | 1 |
| Bone diseases | D001847 | — | M89.9 | — | — | 1 | — | — | 1 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | 1 | — | — | 1 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | 1 | — | — | 1 |
| Aids-related complex | D000386 | EFO_0007137 | B20 | — | — | 1 | — | — | 1 |
| Sexual behavior | D012725 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Genetic therapy | D015316 | — | — | 1 | 1 | — | — | 1 | 2 |
| Systemic scleroderma | D012595 | EFO_0000717 | M34 | — | 1 | — | — | — | 1 |
| Raynaud disease | D011928 | EFO_1001145 | I73.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemarthrosis | D006395 | EFO_1001344 | M25.0 | — | — | — | — | 1 | 1 |
| Thrombosis | D013927 | — | — | — | — | — | — | 1 | 1 |
| Antibiotic prophylaxis | D019072 | — | — | — | — | — | — | 1 | 1 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | — | — | 1 | 1 |
| Afibrinogenemia | D000347 | — | D68.2 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Human coagulation factor viii/von willebrand factor complex |
| INN | — |
| Description | Voncento (human coagulation factor viii/von willebrand factor complex) is an unknown pharmaceutical. Human coagulation factor viii/von willebrand factor complex was first approved as Voncento on 2013-08-12. It has been approved in Europe to treat hemophilia a and von willebrand diseases. |
| Classification | Unknown |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4298129 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,041 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use